These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 15183340)

  • 1. Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.
    Rezende LF; Prasad VR
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1716-34. PubMed ID: 15183340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J; Martínez MA
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
    Menéndez-Arias L
    Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1.
    Turner D; Brenner B; Wainberg MA
    J Antimicrob Chemother; 2004 Jan; 53(1):53-7. PubMed ID: 14645322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs.
    Sarafianos SG; Hughes SH; Arnold E
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1706-15. PubMed ID: 15183339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
    Liu J; Yue J; Wu S; Yan Y
    Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.
    Sato H; Tomita Y; Ebisawa K; Hachiya A; Shibamura K; Shiino T; Yang R; Tatsumi M; Gushi K; Umeyama H; Oka S; Takebe Y; Nagai Y
    J Virol; 2001 Jun; 75(12):5604-13. PubMed ID: 11356968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Parrotta L; Perno CF; Svicher V
    Drug Resist Updat; 2011 Jun; 14(3):141-9. PubMed ID: 21295512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
    Prado JG; Franco S; Matamoros T; Ruiz L; Clotet B; Menéndez-Arias L; Martínez MA; Martinez-Picado J
    Virology; 2004 Aug; 326(1):103-12. PubMed ID: 15262499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
    Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
    J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
    Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different resistance mutations can be detected simultaneously in the blood and the lung of HIV-1 infected individuals on antiretroviral therapy.
    White NC; Israel-Biet D; Coker RJ; Mitchell DM; Weber JN; Clarke JR
    J Med Virol; 2004 Mar; 72(3):352-7. PubMed ID: 14748057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insertions in the beta3-beta4 loop of reverse transcriptase of human immunodeficiency virus type 1 and their mechanism of action, influence on drug susceptibility and viral replication capacity.
    Eggink D; Huigen MC; Boucher CA; Götte M; Nijhuis M
    Antiviral Res; 2007 Aug; 75(2):93-103. PubMed ID: 17416429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
    de Mendoza C; Jiménez-Nacher I; Garrido C; Barreiro P; Poveda E; Corral A; Zahonero N; González-Lahoz J; Soriano V
    Clin Infect Dis; 2008 Jun; 46(11):1782-5. PubMed ID: 18426370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.